KRAS G12D peptide-HLA-C*08:02 complex (KRAS G12D-HLA-C*08:02)

The **KRAS G12D peptide-HLA-C*08:02 complex** is a tumor-specific peptide-major histocompatibility complex (pMHC) comprising a KRAS protein fragment carrying the cancer-driving G12D mutation, presented by the HLA-C*08:02 class I molecule. The mutation-generated aspartate at position 12 of KRAS creates a critical anchor residue, enabling high-affinity binding to HLA-C*08:02 and generating a neoantigen exclusively found in tumor cells with this mutation[1][2][3][4]. This complex is recognized by specific T cell receptors (TCRs), making it a validated target for adoptive T cell therapies in cancer, particularly where both the KRAS G12D mutation and HLA-C*08:02 allele are present. Unique conformations of the presented peptide result in highly specific T cell responses, with minimal cross-reactivity to wild-type KRAS, forming the mechanistic basis for targeting this neoantigen in precision immunotherapy[1][2][3][5].

Other names

KRAS G12D neoantigen-HLA-C*08:02 complexKRAS G12D-HLA-C*08:02 pHLA complexKRAS G12D peptide presented by HLA-C*08:02

T cell receptor binding to neoantigen–HLA complex triggers T cell activation and immune-mediated killing of KRAS G12D mutant tumor cells[1][2][3][5].